Subject	Predicate	Object
AU8PJo1i	a	Resource
		Answer
		Written answer
	answer has question	QJt4OqII
	answer has answering person	William James Quince
	answer text	<p>No specific assessment has been made. The availability of medicines on the National Health Service in Scotland is a matter for the devolved administration. The National Institute for Health and Care Excellence (NICE) is currently developing guidance for the NHS in England on the use of daratumumab plus bortezomib, cyclophosphamide and dexamethasone (Dara-CyBorD) for the treatment of newly diagnosed systemic amyloid light-chain amyloidosis in adults. NICE’s draft recommendations published in December 2022 did not recommend use of Dara-CyBorD and are currently subject to an appeal lodged by the company and Myeloma UK.</p>
	answer given date	2023-06-19
	answer has answering body	Department of Health and Social Care
	written answer has answering body	Department of Health and Social Care
Department of Health and Social Care	answering body has written answer	AU8PJo1i
Department of Health and Social Care	answering body has answer	AU8PJo1i
QJt4OqII	question has answer	AU8PJo1i
William James Quince	answering person has answer	AU8PJo1i